Clinical trials: Lymph Node Cancer Metastatic
Immune Microenvironment, Luminal A
Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer
Luminal type A breast cancer is a type with good clinical prognosis, and the proportion of lymph node metastasis is low, but a small number of patients have more lymph node metastasis when the primary tumor is very small, and the…
- Conditions
- Immune Microenvironment, Luminal A, Lymph Node Metastases
- Trial name
- NCT04322331
- Testing
- no intervention
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Lymph Node Metastases
Lymph Node Metastases and Arterial Ligation in Rectal Cancer Surgery
Lymph node status is of major prognostic importance in non-metastatic rectal cancer. For oncological reasons, central arterial ligation of the inferior mesenteric artery (IMA) is suggested.
- Trial name
- NCT03314961
- Volunteers
- 151 people
- Sponsor
- Region Västmanland
Lymph Node Metastasis
Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell Carcinoma
Existing models do poorly when it comes to quantifying the risk of Lymph node metastases (LNM). This study generated elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble)…
- Trial name
- NCT06256185
- Testing
- esophagectomy
- Where
- China
- Volunteers
- 1,267 people
- Sponsor
- Shanghai Zhongshan Hospital
Papillary Thyroid Cancer, Lymph Node Metastases
Evaluation of Accuracy of One-Step Nucleic Acid Amplification (OSNA) in Diagnosis of Lymph Node Metastases of Papillary Thyroid Carcinoma
The incidence of node metastases in papillary thyroid carcinoma (PTC) is high, ranging from 20% to 90%. Prophylactic central lymph node compartment dissection (CLND), suggested from the latest guidelines for high-risk tumors…
- Trial name
- NCT03889769
- Testing
- OSNA test
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Cagliari
Rectum Cancer
A Lymph Node Metastasis Predictor (LN-MASTER) in Rectal Cancer
In this study, we aim to develop and validate an easy-to-use machine learning prediction model to preoperatively identify the lymph node metastasis status for rectal cancer patients by using these clinical data from three…
- Trial name
- NCT05493930
- Testing
- The hospital where the treatment is performed
- Volunteers
- 6,578 people
- Sponsor
- Peking Union Medical College
Melanoma, Skin Cancer
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00002882
- Testing
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center